Clinical Trial Supply In The EU And U.K.: A Regulatory Guide

By Dr. Mohammad Zaher Shehab, Director, Elevion Pharma

Clinical trial supply is a critical component of successful clinical development. It encompasses the planning, manufacture, packaging, labeling, storage, distribution, accountability, and return or destruction of investigational medicinal products (IMPs) and auxiliary medicinal products used in clinical studies. An effective clinical supply strategy ensures that trial participants receive the correct product at the correct time while maintaining product quality, patient safety, and regulatory compliance.

The regulatory environment governing clinical trial supplies in Europe has undergone significant transformation in recent years. The implementation of the EU Clinical Trials Regulation (EU) No. 536/2014 (CTR) and the U.K.'s updated Clinical Trials Regulations in April 2026 have introduced new opportunities for harmonization and efficiency, while also creating operational challenges for sponsors running multinational studies. Organizations must now navigate two distinct but closely aligned regulatory frameworks to ensure uninterrupted supply throughout the clinical trial life cycle.

The Importance Of Clinical Trial Supply Management

Clinical trial supply management extends far beyond the manufacture of investigational products. It requires the integration of multiple functions including regulatory affairs, clinical operations, quality assurance, manufacturing, logistics, and pharmacovigilance.

Poor supply planning can result in:

• delayed patient recruitment
• site stock shortages
• product wastage due to expiry
• increased study costs
• protocol deviations
• regulatory findings during inspections.

Conversely, a robust supply chain enables sponsors to maximize patient recruitment, minimize waste, maintain compliance, and achieve development milestones on schedule.

As clinical trials become increasingly global and more complex, supply chains must accommodate multiple dosing regimens, varying recruitment rates, direct-to-patient models, temperature-controlled products, and increasingly sophisticated biologic and advanced therapy medicinal products (ATMPs).

The EU Regulatory Framework

The introduction of the EU Clinical Trials Regulation has fundamentally changed the conduct of clinical trials across the European Economic Area. The CTR replaced the Clinical Trials Directive and established a harmonized framework for the assessment and supervision of clinical trials across EU Member States.

One of the most significant changes is the use of the Clinical Trials Information System (CTIS), which provides a single portal for submitting and managing clinical trial applications across participating countries. Sponsors can now submit one application for a multinational study rather than separate applications to each Member State.

From a clinical supply perspective, the CTR has increased the need for:

• early demand forecasting
• coordinated labeling strategies
• harmonized supply planning across multiple countries
• robust change management processes
• improved transparency regarding trial status and country participation.

As all EU clinical trials now operate under the CTR framework, sponsors must ensure that supply chain processes are fully aligned with CTIS submissions, approved trial documentation, and country-specific operational requirements.

Clinical Trial Supply Requirements In The EU

Manufacturing And Qualified Person Certification

Investigational medicinal products intended for use in EU clinical trials must generally be manufactured in accordance with EU good manufacturing practice (GMP).

Each batch of IMP typically requires certification by a qualified person (QP) before release for use in a clinical trial. The QP confirms that manufacturing, testing, and release activities comply with GMP requirements and the clinical trial authorization.

This certification process remains a cornerstone of the European clinical trial supply system and provides assurance that products meet predefined quality standards before reaching patients.

Labeling Requirements

IMPs must be labelled in accordance with the CTR and Commission Delegated Regulation (EU) 2017/1569. Labels must contain specific information to ensure traceability, patient safety, and proper administration.

Key information may include:

• trial identification
• investigator or sponsor details
• storage conditions
• expiry or retest dates
• product usage instructions.

The CTR has introduced greater flexibility regarding label content, particularly for decentralized and low-intervention studies, helping reduce operational burden while maintaining patient protection.

Importation And Distribution

Products manufactured outside the EU require appropriate importation arrangements and certification before distribution into Member States. Sponsors must ensure that approved depots, logistics providers, and QP release processes are established in advance of study initiation.

Supply chain resilience has become increasingly important due to geopolitical factors, transportation challenges, customs procedures, and fluctuating demand patterns.

The U.K. Regulatory Framework

Following Brexit, the U.K. established an independent regulatory pathway for clinical trials. While many principles remain aligned with the EU framework, clinical trial approvals are managed separately by the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committees.

The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 came fully into force on April 28, 2026 and represent the largest overhaul of U.K. clinical trial legislation in over two decades. The reforms aim to improve efficiency, reduce administrative burden, and enhance the U.K.'s attractiveness as a destination for clinical research.

The reforms include:

• accelerated review timelines
• streamlined approval pathways
• risk-proportionate regulatory oversight
• new provisions for low-risk and notifiable trials
• greater alignment with international regulatory standards.

These developments are expected to support faster trial start-up while maintaining high standards of participants’ safety and data integrity.

Clinical Trial Supply Considerations In The U.K.

IMP Importation And Oversight

Since the U.K.'s departure from the EU, sponsors must carefully consider IMP importation pathways.

For IMPs imported into Great Britain, appropriate oversight arrangements are required through a U.K. MIA(IMP) holder. Regulatory responsibilities differ depending on the country of manufacture and supply route.

Sponsors planning multinational EU-U.K. studies often establish parallel supply chains to ensure continuity and flexibility.

Labeling Requirements

The MHRA has updated guidance relating to IMP labeling under the revised clinical trial framework. Sponsors must ensure that clinical supplies comply with U.K.-specific requirements and that any post-approval label updates undergo appropriate assessment and documentation.

The increasing use of risk-based approaches means that supply chain changes, including labeling modifications, should be supported by documented assessments demonstrating that quality and participant safety are maintained.

Supply Continuity And Risk Management

Supply continuity remains a major focus area for U.K. clinical trials. Sponsors are expected to implement risk-based approaches to identify and mitigate potential disruptions.

Common risk mitigation strategies include:

• dual sourcing of critical materials
• strategic stock placement
• safety stock calculations
• secondary packaging capabilities
• alternative distribution routes
• robust temperature monitoring systems.

Emerging Trends In Clinical Trial Supply

The clinical supply environment continues to evolve rapidly. Several trends are shaping the future of clinical trial supply in both the EU and U.K.:

Decentralized Clinical Trials

The adoption of decentralized and hybrid trial models has increased the need for direct-to-patient distribution, home healthcare support, and digital accountability tools. Supply chains must now facilitate product delivery directly to participants while maintaining full regulatory compliance and product integrity.

Advanced Therapies

Growth in gene therapies, cell therapies, and personalized medicinal products presents unique supply challenges. These products often have short shelf lives, specialized storage conditions, and highly patient-specific manufacturing processes.

Digital Supply Chain Technologies

Predictive analytics, artificial intelligence, real-time temperature monitoring, and integrated inventory management platforms are improving supply visibility and enabling more accurate forecasting.

Sustainability

Sponsors and service providers are increasingly seeking opportunities to reduce waste, improve packaging efficiency, and reduce the environmental impact of clinical trial logistics.

Role Of The Regulatory Affairs Function In Ensuring Clinical Trial Supply Continuity

The regulatory affairs function plays a central role in safeguarding clinical trial supply across both the EU and U.K. frameworks. As the owners of the clinical trial authorization strategy, regulatory teams ensure that supply chain activities remain fully aligned with approved protocols, IMP dossiers, labeling requirements, and country‑specific operational expectations. Under the EU CTR, regulatory teams are responsible for maintaining consistency between CTIS submissions, QP‑certified batch documentation, and any supply‑related amendments that may affect the trial’s conduct. In the U.K., regulatory leads oversee compliance with MHRA’s updated 2026 clinical trial regulations, including oversight of MIA(IMP) importation routes, risk‑proportionate labeling updates, and supply‑related substantial modifications.

Critical considerations that regulatory teams must anticipate include early forecasting of IMP quantities based on recruitment projections, cross‑country harmonization of labels, timely management of protocol or manufacturing changes, and ensuring that supply chain partners (depots, QPs, distributors) operate within the boundaries of the authorized trial documentation. As the primary interface with health authorities, regulatory affairs professionals lead cross‑functional coordination, proactively identify risks such as import delays, label deviations, or temperature excursion reporting obligations, and ensure that all supply decisions remain compliant, documented, and defensible during inspections. Their strategic oversight is essential to maintaining uninterrupted supply, protecting patient safety, and enabling efficient trial execution across the evolving EU and U.K. regulatory landscapes.

Conclusion

Clinical trial supply has become a strategic function that directly influences study timelines, participant recruitment, regulatory compliance, and overall development costs. The implementation of the EU Clinical Trials Regulation and the U.K.'s updated clinical trial framework has modernized the regulatory landscape, creating new opportunities for efficiency while introducing additional operational considerations.

Success in today's environment requires early planning, cross-functional collaboration, robust quality systems, and a comprehensive understanding of both EU and U.K. requirements. Organizations that invest in resilient, flexible, and patient-focused supply strategies will be best positioned to support the next generation of clinical research and accelerate patient access to innovative medicines.

About The Author:

Dr. Mohammad Zaher Shehab is a senior Regulatory Affairs expert with more than a decade of UK, EU and global experience spanning clinical development, PIPs, Marketing Authorisation Applications (MAAs), lifecycle management, Scientific advice and health authority interactions and rare‑disease regulatory strategy. He has held key regulatory roles at Gilead, AstraZeneca, Pfizer, MSD, Alexion and Teva, leading regional strategies and delivering high‑quality submissions across multiple therapeutic areas including virology, oncology and ATMPs.

He is the Director of Elevion Pharma, a UK‑based regulatory consultancy supporting pharmaceutical and biotech companies across the UK, EU and MENA regions. Elevion Pharma specialises in regulatory strategy, clinical trial support, MAAs, lifecycle management, CMC guidance and rare‑disease regulatory pathways, helping organisations accelerate approvals and navigate complex global regulatory frameworks with clarity and confidence.

If you want to learn how Elevion Pharma can support your clinical development and submission strategy, please contact us at info@elevionpharma.com.